Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Produ...(ulture device designed by Chris Fraker s...),Health

Date:9/5/2007

ulture device, designed by Chris Fraker, senior research associate in the Tissue Engineering Laboratory at the Diabetes Research Institute, closely mimics the natural oxygen environment. The device "sandwiches" the stem cells with oxygen from two sources, one from the top with air diffusing through the culture medium and the second from the bottom with air diffusing through a silicon membrane mixed with perfluorocarbon, a very powerful oxygen reservoir.

"The use of high oxygen to promote differentiation of insulin-producing cells opens the way to many other applications with different sources of progenitor cells, beyond embryonic stem cells and beyond diabetes," said Camillo Ricordi, M.D., scientific director of the Diabetes Research Institute.

About the Diabetes Research Institute

The Diabetes Research Institute is a recognized world leader in cure- focused research. Since its inception in the early 1970s, the DRI has made significant contributions to the field of diabetes research, pioneering many of the techniques used in islet transplantation. From innovations in islet isolation and transplant procedures to advances in cell biology and immunology, the DRI is now harnessing the power of emerging technologies to develop new cell-based therapies to restore insulin production. For the millions of families already affected by diabetes who are looking to the world of science for answers, the Diabetes Research Institute is the best hope for a cure.

'/>"/>

SOURCE Diabetes Research Institute Foundation Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
5. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes